Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664538 | 0.95 | MAPT (0.37) | EGFRBTKMAPTAKR1B1RORC | |
| SCHEMBL31664566 | 0.94 | MAPT (0.36) | EGFRBTKMAPTAKR1B1RORC | |
| SCHEMBL31664545 | 0.93 | MAPT (0.36) | EGFRBTKMAPTAKR1B1RORC | |
| SCHEMBL31664569 | 0.89 | JAK3 (0.38) | BTKMAPTTGM2NR3C1 | |
| SCHEMBL31664568 | 0.89 | JAK3 (0.38) | BTKMAPTTGM2NR3C1 | |
| SCHEMBL31713847 | 0.88 | EGFR (0.37) | EGFRBTKMAPTAKR1B1RORC | |
| SCHEMBL31664573 | 0.86 | AKR1B1 (0.39) | MAPTAKR1B1RORCPOLBTDP1 | |
| SCHEMBL31713755 | 0.83 | AKR1B1 (0.40) | MAPTAKR1B1KDM4ETP53PTGDR2 | |
| SCHEMBL31713795 | 0.82 | MAPT (0.37) | EGFRBTKMAPTAKR1B1RORC | |
| SCHEMBL31664549 | 0.82 | MAPT (0.36) | MAPTAKR1B1RORCPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-24 | — | — | US | claimed |
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | EGFR 4764/4885BTK 2690/4885MAPT 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.